Zacks Investment Research Lowers Endo International (ENDP) to Hold
Endo International (NASDAQ:ENDP) (TSE:ENL) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued to investors on Tuesday.
According to Zacks, “Endo is in the process of redefining its business, given the persistent decline in the generic business and withdrawal of opioid pain medication Opana ER (oxymorphone hydrochloride extended release) from the market following FDA’s request in June 2017. The focus now is on sterile injectables and Xiaflex. Sales of Xiaflex are being driven by increased demand in both Peyronie's disease and Dupuytren's contracture. Revenues from the sterile injectables business are being driven by the continued growth of Adrenalin. The business is poised to become Endo's core business. While the turnaround might take time, the company seems to be on the right track. Shares have outperformed the industry in the year so far. However, the generic business is expected to face further challenges. Competition is expected to intensify further in 2018.”
A number of other equities research analysts have also recently issued reports on the company. Deutsche Bank set a $11.00 target price on Endo International and gave the stock a “buy” rating in a research report on Wednesday, July 18th. ValuEngine raised Endo International from a “strong sell” rating to a “sell” rating in a research report on Wednesday, July 25th. BidaskClub cut Endo International from a “strong-buy” rating to a “buy” rating in a research report on Saturday, September 8th. Morgan Stanley upped their target price on Endo International from $7.00 to $17.00 and gave the stock an “equal weight” rating in a research report on Friday, August 17th. Finally, Canaccord Genuity set a $13.00 target price on Endo International and gave the stock a “hold” rating in a research report on Wednesday, August 1st. Sixteen equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average target price of $14.07.
Endo International (NASDAQ:ENDP) (TSE:ENL) last announced its quarterly earnings results on Wednesday, August 8th. The company reported $0.76 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.54 by $0.22. The business had revenue of $714.70 million during the quarter, compared to analysts’ expectations of $679.72 million. Endo International had a positive return on equity of 237.45% and a negative net margin of 34.72%. The firm’s quarterly revenue was down 18.4% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.93 EPS. analysts predict that Endo International will post 2.6 EPS for the current year.
In other news, Director Roger H. Kimmel sold 26,074 shares of the company’s stock in a transaction that occurred on Tuesday, August 14th. The stock was sold at an average price of $15.90, for a total transaction of $414,576.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 0.80% of the stock is owned by insiders.
Hedge funds and other institutional investors have recently modified their holdings of the stock. Diamond Hill Capital Management Inc. raised its stake in shares of Endo International by 1.0% in the second quarter. Diamond Hill Capital Management Inc. now owns 1,100,259 shares of the company’s stock valued at $10,375,000 after purchasing an additional 10,600 shares in the last quarter. New York State Teachers Retirement System raised its stake in shares of Endo International by 27.0% in the second quarter. New York State Teachers Retirement System now owns 356,957 shares of the company’s stock valued at $3,366,000 after purchasing an additional 75,844 shares in the last quarter. Sivik Global Healthcare LLC acquired a new position in shares of Endo International in the second quarter valued at $1,697,000. Flinton Capital Management LLC raised its stake in shares of Endo International by 84.2% in the first quarter. Flinton Capital Management LLC now owns 55,998 shares of the company’s stock valued at $333,000 after purchasing an additional 25,602 shares in the last quarter. Finally, Bank of New York Mellon Corp grew its position in Endo International by 13.2% in the second quarter. Bank of New York Mellon Corp now owns 2,446,852 shares of the company’s stock valued at $23,074,000 after acquiring an additional 284,599 shares during the period. Institutional investors and hedge funds own 98.43% of the company’s stock.
About Endo International
Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States, Canada, and internationally. The company operates through three segments: U.S. Generic Pharmaceuticals, U.S. Branded Pharmaceuticals, and International Pharmaceuticals.
Recommended Story: Understanding Compound Annual Growth Rate (CAGR)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with MarketBeat.com's FREE daily email newsletter.